Fully automated, sample‐to‐answer platform for the quantitation of blood‐based biomarkers for early detection of Alzheimer's disease

We used dcPLA to detect and quantify endogenous pTau-217 levels in seven healthy plasma samples acquired from a commercial source with high consistency and high signal-to-noise ratio. (Figure 2) Additionally, we demonstrated a fully automated sample-to-answer diagnostics platform using the novel dcPLA with a single, streamlined workflow. The platform can process up to 48 samples in a single batch, in around five hours and requires no hands-on time beyond the initial loading of samples and reagents. Here we demonstrate an automated spike and recovery experiment show close to 100% recovery with 3X diluted plasma. (Figure 3) CONCLUSION: Here, we present the first AD-focused diagnostic platform combining an FDA-approved Class 1 sample-to-answer system with the novel dcPLA technology. By enabling minimally invasive and scalable testing, the platform has the potential to assist drug developers recruiting the right patients for their clinical trials, paving the way toward early detection, longitudinal monitoring, and personalized treatment strategies to improve AD patient outcome worldwide.